These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 34949115)

  • 1. Performance-based risk-sharing arrangements for devices and diagnostics in the United States: a systematic review.
    Chen Y; Carlson JJ
    J Manag Care Spec Pharm; 2022 Jan; 28(1):78-83. PubMed ID: 34949115
    [No Abstract]   [Full Text] [Related]  

  • 2. Performance-Based Risk-Sharing Arrangements for Pharmaceutical Products in the United States: A Systematic Review.
    Yu JS; Chin L; Oh J; Farias J
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1028-1040. PubMed ID: 28944733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance-Based Risk-Sharing Arrangements: U.S. Payer Experience.
    Goble JA; Ung B; van Boemmel-Wegmann S; Navarro RP; Parece A
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1042-1052. PubMed ID: 28944728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers.
    Carlson JJ; Gries KS; Yeung K; Sullivan SD; Garrison LP
    Appl Health Econ Health Policy; 2014 Jun; 12(3):231-8. PubMed ID: 24664994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance-Based Risk-Sharing Arrangements: An Updated International Review.
    Carlson JJ; Chen S; Garrison LP
    Pharmacoeconomics; 2017 Oct; 35(10):1063-1072. PubMed ID: 28695544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance-Based Risk-Sharing Arrangements (PBRSA): Is it a Solution to Increase Bang for the Buck for Pharmaceutical Reimbursement Strategy for Our Nation and Around the World?
    Kim AE; Choi DH; Chang J; Kim SH
    Clin Drug Investig; 2020 Dec; 40(12):1107-1113. PubMed ID: 33037566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International experience with performance-based risk-sharing arrangements: implications for the Chinese innovative pharmaceutical market.
    Xu W; Wu J
    Int J Technol Assess Health Care; 2020 Oct; 36(5):486-491. PubMed ID: 32962784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes-Based Contracting Experience: Research Findings from U.S. and European Stakeholders.
    Nazareth T; Ko JJ; Sasane R; Frois C; Carpenter S; Demean S; Vegesna A; Wu E; Navarro RP
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1018-1026. PubMed ID: 28944734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.
    Garrison LP; Carlson JJ; Bajaj PS; Towse A; Neumann PJ; Sullivan SD; Westrich K; Dubois RW
    Am J Manag Care; 2015 Sep; 21(9):632-40. PubMed ID: 26618366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States.
    Brown JD; Sheer R; Pasquale M; Sudharshan L; Axelsen K; Subedi P; Wiederkehr D; Brownfield F; Kamal-Bahl S
    Value Health; 2018 Jan; 21(1):33-40. PubMed ID: 29304938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
    Critchley GJ; Zaric GS
    Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance-based risk-sharing agreements in renal care: current experience and future prospects.
    Drummond M; Federici C; Busink E; Apel C; Kendzia D; Brouwer W
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):197-209. PubMed ID: 33439090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Payer perceptions on the use of patient-reported outcomes in oncology decision making.
    Oderda G; Brixner D; Biskupiak J; Burgoyne D; Arondekar B; Deal LS; Quek RG; Niyazov A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):188-195. PubMed ID: 34806908
    [No Abstract]   [Full Text] [Related]  

  • 17. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan.
    Strohbehn GW; Cooperrider JH; Yang D; Fendrick AM; Ratain MJ; Zaric GS
    Value Health Reg Issues; 2022 Sep; 31():34-38. PubMed ID: 35395499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance-based risk-sharing arrangements for devices and procedures in cardiac electrophysiology: an innovative perspective.
    Boriani G; Vitolo M; Svennberg E; Casado-Arroyo R; Merino JL; Leclercq C
    Europace; 2022 Oct; 24(10):1541-1547. PubMed ID: 35531864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.